Publication at First Faculty of Medicine |
2021
Abstract
This case report of a patient with metastatic, BRAF V600 mutated melanoma represents an example of the sequential therapy. The patient was treated with immunotherapy (with pembrolizumab and ipilimumab) in combination with intralesional therapy, afterwards with combinational chemotherapy and subsequently with two combinations of targeted drugs (dabrafenib plus trametinib, encorafenib plus binimetinib).
A review of clinical trials showing high efficacy of the administered drugs is discussed. Current options of systemic anticancer therapy allow to conduct sequential therapy of metastatic melanoma with significant prolongation of progression free survival and with improvement of quality of life.